CN1056298C - External use medicine for treating soft tissue injury and its producing method - Google Patents
External use medicine for treating soft tissue injury and its producing method Download PDFInfo
- Publication number
- CN1056298C CN1056298C CN96123078A CN96123078A CN1056298C CN 1056298 C CN1056298 C CN 1056298C CN 96123078 A CN96123078 A CN 96123078A CN 96123078 A CN96123078 A CN 96123078A CN 1056298 C CN1056298 C CN 1056298C
- Authority
- CN
- China
- Prior art keywords
- medicine
- soft tissue
- tissue injury
- water preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses an externally applied medicine for treating soft tissue injury and a production method thereof. The medicine contains coptis, phellodendron bark, gardenia, alkanna tinctoria, etc., and is produced by alcohol extraction and sterilization for microporous filtering films. The medicine can be made into liquid medicine, ointment, membrane medicine, plaster, atc. The medicine of the present invention has the advantages of safety, no toxicity, good moisture holding performance, obvious therapeutic effect, and wide range of application, and has unique therapeutic effect on clearing heat and detoxication, dispersing swelling and alleviating pain, activating blood circulation to dissipate blood stasis, eliminating necrotic tissues and promoting granulation. The effective rate of the medicine reaches 95.74% according to the statistic analysis of 260 cases. The production method of the present invention has a reasonable design.
Description
The present invention relates to a kind of pharmaceutical composition for the treatment of soft tissue injury, specifically is the external Chinese patent medicine of the treatment soft tissue injury made of raw material with the Chinese herbal medicine; The invention still further relates to this medicine production method.
Soft tissue injury is commonly encountered diseases, the frequently-occurring disease of traumatology, and fracture or dislocation equivalent damage often are associated with serious soft tissue injury.Modern medicine mainly adopts the operation debridement to open soft tissue injury, prevents traumatic infection with nitrofural, 75% ethanol, benzalkonium bromide, ethacridine etc. in early days; The protection of external vaseline oil yarn promotes the granulation tissue growth.To closed soft tissue injury then mainly with means such as braking, local freezing naturopathy.The traditional medicine external treatment many based on Chinese medicine loose, cream, tincture, be only applicable to closed soft tissue injury.Through the Chinese medicine documentation retrieval centre's update search of State Administration of Traditional Chinese Medicine China, domestic have the document that uses Chinese medicine water preparation and liniment treated soft tissue injury, but all be that treatment closed soft tissue injury or crude preparation by using are (as the freezing Cape jasmine acid solution of Zhang Shi [for water decoction], orthopedics and traumatology of Chinese medicine magazine 1987; (1): 38; The red Radix Et Rhizoma Rhei liniment of Shang Shi Cape jasmine [being tincture], the Shaanxi traditional Chinese medical science 1994; 15 (6): 256; Young disappear ichor [for tincture], external treatment with Chinese medicine magazine 1995; (4): 11; Hou Shi damage liquefaction film [for containing pure liniment], Chinese traditional Chinese medical science bone injury magazine 1995; 3 (5): 1).
Chinese patent application 92112763 disclosed musk shuhuo essences are tincture, scientific and technological achievement Radix Angelicae Pubescentis liniment (serial number: 787) be external-use oil preparation, all only be applicable to closed soft tissue injury.Up to now, still do not have on the domestic and international market a kind of generally acknowledged, not only be suitable for open soft tissue injury but also be suitable for external Chinese medicine water preparation or ointment, the membrane etc. of closed soft tissue injury.
The shortcoming that the purpose of this invention is to provide the medicine that overcomes present treatment soft tissue injury provides a kind of open soft tissue injury that both can be used for, and is applicable to closed soft tissue injury again, has the medicine for external use of good curative effect.
Another object of the present invention provides the production method of this soft tissue injury curative.
The present invention realizes like this.
The employing medicine be Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Alumen, Mentholum as principal agent, the medicine for external use of making, preparation formulation are exterior-applied formulations such as water preparation, ointment, plaster, membrane.After increasing dosage again, also can adopt dosage forms for oral administration such as tablet, capsule, oral liquid, electuary.
When preparation of the present invention is the external water preparation, can adopt tween, arabic gum, tragakanta, glycerol etc. to make suspending agent (solubilizing agent), be good with glycerol, because glycerin preparation on spreading upon skin the time, has moisture-keeping function concurrently.
Water preparation of the present invention can also add antiseptic, as parabens, benzoic acids or phenols, is good with ethylparaben (being ethyl hydroxybenzoate) wherein.
Also can add Percutaneous absorption enhancer such as azone (azone) in the preparation of the present invention.
Medicine of the present invention is made (consumption is a weight ratio) by following component: 10～20 parts of Rhizoma Coptidis, 8～15 parts of Cortex Phellodendris, 8～15 parts of Fructus Gardeniaes, 8～15 parts of Radix Arnebiae (Radix Lithospermi)s, 2～5 parts of Alumens (Alumen), 0.05～0.1 part of Mentholum.
The preferential weight ratio scope of medicine of the present invention is: 12～18 parts of Rhizoma Coptidis, 10～12 parts of Cortex Phellodendris, 10～12 parts of Fructus Gardeniaes, 10～12 parts of Radix Arnebiae (Radix Lithospermi)s, 3～4 parts of Alumens (Alumen), 0.07～0.08 part of Mentholum.
The best proportioning of medicine external water preparation of the present invention is: Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 3.42kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg add water and are made into 230～920 premium on currency agent.
The production method of medicine external water preparation of the present invention is:
(1) get Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae pulverizing, add 10 times of amount 70% alcohol heating reflux 2 times,
Filter, filtering residue discards;
(2) get Radix Arnebiae (Radix Lithospermi) in addition and be cut into 1～2cm segment, add 10 times of amount 70% alcohol at normal temperature and soak 2 times,
Filter, filtering residue discards;
(3) Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) filtrate are merged, 60～80 ℃ of decompression recycling ethanols add Alumen to the greatest extent;
(4) get Mentholum, ethylparaben and add after with a small amount of 95% dissolve with ethanol, capacity transfer fully stirs to 90～93% of capacity, leaves standstill 24 hours in 0～4 ℃, and filter press adds glycerol again, fully stirs;
(5) use the microporous filter membrane degerming, aseptic subpackaged, get product.
Pondage to capacity 90～93% after, regulating pH is between 3.7～4.0.
The aperture of microporous filter membrane is 0.45 μ m.
Solution of the present invention is based on understanding and the Therapeutic Principle of motherland's medical science to falling the etiology and pathogenesis of pouncing on wound, by the theory of Chinese medical science prescription, filter out one group of Chinese herbal medicine of heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting effect, according to the modern pharmacological research achievement, adopt the preparation process of science and a kind of medicine for external use for the treatment of opening and closed soft tissue injury of developing.Said preparation is reused Rhizoma Coptidis with heat-clearing and toxic substances removing, the dampness detumescence; Help the merit of Rhizoma Coptidis heat-clearing and toxic substances removing, dampness detumescence with Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) are held concurrently can removing heat from blood and promoting blood circulation, promotes blood circulation to change block up; Alumen detoxifcation putrefaction removing, the convergence granulation promoting; The hot cold of Herba Menthae is loose wind-expelling pain-stopping, and the energy that helps the Radix Arnebiaeization block up to promote blood circulation with light clear a surname.We's prescription is rigorous, makes a distinction between the important and the lesser one, and plays the merit of heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting altogether.Cure mainly pain caused by ecchymoma that various traumatic injury cause, hemorrhage; And to because of invade in wind (heat) poison the rotten blood of (burn and scald) or stagnation of blood stasis and heat, meat lose the soft tissue that causes red, swollen, hot, bitterly in addition disease such as suppuration ideal curative effect is arranged.Through modern pharmacological research, this medicine has infection, antiinflammatory, analgesia, the growth of promotion wound surface granulation tissue, microcirculation disturbance is had a better role, no obvious toxic and side effects, and curative effect is fast.
Narrate embodiment below.
Embodiment 1
Take by weighing raw material by following proportioning: Rhizoma Coptidis 35kg, Cortex Phellodendri 25kg, Fructus Gardeniae 25kg, Radix Arnebiae (Radix Lithospermi) 25kg, Alumen 7.5kg, Mentholum 0.2kg, glycerol 100.55kg, ethylparaben 1kg, make 1000000ml.
Get the granule that Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae are ground into the Semen Glycines size, add 10 times of amount 70% alcohol heating reflux 2 times, each 1 hour, filter, filtering residue discards; Other gets Radix Arnebiae (Radix Lithospermi) is cut into 1～2cm segment, and add 10 times of amount 70% alcohol at normal temperature and soak 2 times, each 24 hours, filter, filtering residue discards; Merge above filtrate, 65 ℃ of decompression recycling ethanols are to most.Add Alumen; Getting Mentholum, ethylparaben adds after with a small amount of 95% dissolve with ethanol; Capacity transfer is to 92% of capacity, and transferring pH is 3.85, fully stirs, and leaves standstill 24 hours in 0～4 ℃, and filter press stirs behind the glycerol adding; After the microporous filter membrane degerming of 0.45 μ m, aseptic subpackaged, the aluminium lid press seal promptly.
Embodiment 2
Rhizoma Coptidis 16kg, Cortex Phellodendri 11kg, Fructus Gardeniae 11kg, Radix Arnebiae (Radix Lithospermi) 11kg, Alumen (Alumen) 3.5kg, Mentholum 0.09kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, add water solublity or emulsion-type ointment base, make ointment.
Embodiment 3
Rhizoma Coptidis 10kg, Cortex Phellodendri 8kg, Fructus Gardeniae 8kg, Radix Arnebiae (Radix Lithospermi) 15kg, Alumen 5kg, Mentholum 0.1kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, add plaster substrate, make black plaster or rubber ointment.
Embodiment 4
Rhizoma Coptidis 20kg, Cortex Phellodendri 8kg, Fructus Gardeniae 15kg, Radix Arnebiae (Radix Lithospermi) 8kg, Alumen 3kg, Mentholum 0.05kg, preceding four liquid medicine are carried, and concentrate, and add back two medicines, mix with the filmogen serosity, make membrane according to a conventional method.
Embodiment 5
Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 4.2kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg are made into 460 premium on currency agent.
This production method is seen the production method that goes up the external water preparation.
Embodiment 6
Dosage and production method add water and are made into 920 premium on currency agent with embodiment 5.
Rhizoma Coptidis of the present invention, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) also available water are carried.
The administrated method of medicine of the present invention is that the drug ointment agent is applied to affected part (comprising wound surface and closure creation affected part), every day 1～3 time, as be plaster and membrane, then be affixed on the affected part.Every day 1 time.As be water preparation, soak into medicinal liquid with gauze, the external application affected part bandages, and changes dressings every day 1 time, and 20 days is a course of treatment.
An important feature of medicine of the present invention is that pharmacological action is extensive, has:
(1) anti-infectious function.Embodiment 5 and the pyogenic infection of 6 pairs of caused by Staphylococcus aureus mouse skins of embodiment have the obvious treatment effect, and the pathological changes index of infection is obviously reduced, and the necrosis that obviously reduces epidermis, corium, hypodermic necrosis and the appendages of skin destroys.Common traumatic infection pathogen and conditioned pathogen all there is in various degree antibacterial action, wherein stronger to staphylococcus aureus, staphylococcus epidermidis and beta hemolytic streptococcus effect, see Table 1～4, the experimental result prompting: this medical instrument has the effect of heat-clearing and toxic substances removing putrefaction removing.
The table 1. pair caused by Staphylococcus aureus mouse skin pyogenic infection pathological changes information slip (index of group medicine infection lesion (score) of X ± S)
The 3rd day the 5th day the 7th day the 9th day the 11st day physiology saline-2.53 ± the the 0.64th 2.80 ± 0.68 2.77 ± 0.73 2.45 ± 0.52 1.55 ± 0.52 of concentration (%)
(15) (15) (15) (15) (15) muscles relaxing essence 100 2.00 ± 0.53* 2.13 ± 0.35** 2.13 ± 0.35** 1.60 ± 0.51** 0.93 ± 0.73**
(15) (15) (15) (15) (15) embodiment 6 2.33 ± 0.49 2.33 ± 0.62 2.07 ± 0.27**, 1.21 ± 0.47**, 0.89 ± 0.41**
(15) (15) (15) (15) (15) embodiment 5 1.47 ± 0.52** 1.33 ± 0.49** 0.73 ± 0.59** 0.40 ± 0.63** 0.27 ± 0.64**
(15) annotate (15) (15) (15) (15): 1. be number of animals in ().
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
3. the normal saline group is overweight because of infecting in the experiment, 4 dead mouses, and embodiment is 1 death for 6 groups.
(X ± S) group medicine number of animals dermal pathology changes (score) in the influence of table 2. pair caused by Staphylococcus aureus pyogenic infection mice affected skin pathological change
Concentration, (%), downright bad subcutaneous downright bad attached downright bad physiological saline-11 4.0 ± 0 4.0 ± 0 1.6 ± 0.8 4.0 ± 0 muscles relaxing essence, 100 15 3.2 ± 0.4**, 1.8 ± 0.8**, 1.2 ± 0.4 1.2 ± 0.4** embodiment, 6 14 2.6 ± 0.5**, 1.4 ± 0.5**, 1.1 ± 0.4 1.1 ± 0.4** embodiment, 5 15 2.4 ± 0.7**, 1.5 ± 0.5**, 1.0 ± 0.4*, the 1.0 ± 0.2** that destroys that suppurates that suppurates of (only) Epidermal necrosis suppuration corium annotates: 1. skin pathological changes standards of grading:
"-" expression is normal, gets 0 fen;
"+" expression extent of disease got 1 fen in below 1/4 of the visual field;
" ++ " expression extent of disease accounts for about 2/4 of the visual field, gets 2 fens;
" +++" represent that extent of disease accounts for about 3/4 of the visual field, got 3 fens;
" ++ ++ " represent that extent of disease involves whole visual field, got 4 fens.
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 3. pair caused by Staphylococcus aureus pyogenic infection mice affected skin fiber
The influence of hamartoplasia (X ± S)
Group drug level (%) number of animals (only) fibroplasia (score) normal saline-11 0.1 ± 0.3 muscles relaxing essence 100 15 1.0 ± 0.5** embodiment 6 14 1.1 ± 0.6** embodiment 5 15 1.3 ± 0.5** annotates: 1. fibroplasia is divided into level Four:
"-" expression whole visual field is not seen hypertrophy, gets 0 fen;
"+" expression hypertrophy scope got 1 fen in below 1/4 of the visual field;
" ++ " expression hypertrophy scope accounts for about 2/4 of the visual field, gets 2 fens;
" +++" represent that the hypertrophy scope accounts for about 3/4 of the visual field, gets 3 fens;
" ++ ++ " represent that the hypertrophy scope involves whole visual field, gets 4 fens.
2. compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 4. traumatology yellow fluid is to the antibacterial evaluation of traumatic infection encountered pathogenic bacteria and conditioned pathogen
Inhibitory potency
Medicine
The B-mode mucositis large intestine of golden yellow epidermis first type green pus white
Staphylococcus staphylococcus streptococcus streptococcus coccus bacillus bacillus candidiasis embodiment 5,61: 80 1: 40 1: 20 1: 40 1: 10 1: 51: 51: 5 musk shuhuo essences 1: 51: 51: 51: 51: 2.5 1: 2.5 1: 2.5 1: 2.5
(2) antiinflammatory action is arranged.5,6 pairs of histamines of embodiment induced mice capillary of skin permeability increases inhibitory action, and can suppress the mice ear due to the dimethylbenzene; Foot swelling due to embodiment 5,6 PARA FORMALDEHYDE PRILLS(91,95)s and the Ovum Gallus domesticus album has inhibitory action, and see Table 5～8, results suggest: embodiment has the detumescence effect.
Table 5. pair histamine induced mice capillary of skin permeability affect group drug concentration (%) number of animals (only) fibroplasia (score) physiological saline-10 0.359 ± 0.092 muscles relaxing essence 100 10 0.289 ± 0.091 ten thousand caul-fat 100 10 0.171 ± 0.089** embodiment 6 10 0.256 ± 0.071* embodiment 5 10 0.192 ± 0.063**
Annotate: compare * P＜0.05, * * P＜0.01 with the normal saline group.
Table 6. xylol induced mice ear swelling influence the group drug level, (%) number of animals, (only) fibroplasia, (score) normal saline-12 39.6 ± 13.2 muscles relaxing essence 100 10 25.7 ± 13.1* embodiment 6 10 22.1 ± 14.6* embodiment 5 10 22.4 ± 10.9**
Annotate: compare * P＜0.05, * * P＜0.01 with the normal saline group.
The influence of table 7. pair rat Ovum Gallus domesticus album foot swelling
The medicine number of animals causes the scorching back foot swelling degree (group of X ± S)
Concentration, (%), (only) 1 hour 2 hours 5 hours physiological saline-11 0.877 ± 0.135 0.759 ± 0.167 0.391 ± 0.113 muscles relaxing essence 100 10 0.830 ± 0.170 0.695 ± 0.110 0.385 ± 0.120 ten thousand caul-fat 100 10 0.715 ± 0.118** 0.610 ± 0.120*, 0.235 ± 0.103** embodiment, 6 10 0.895 ± 0.145 0.735 ± 0.143 0.355 ± 0.103 embodiment 5 10 0.785 ± 0.167 0.635 ± 0.143 0.285 ± 0.112
Annotate: compare * P＜0.05, * * P＜0.01 with normal saline.
The influence of table 8. pair rat formaldehyde foot swelling
The medicine number of animals causes the scorching back foot swelling degree (group of X ± S)
Concentration, (%), (only) the 2nd day the 3rd day the 4th day the 5th day physiology salt solution-10 0.770 ± 0.158 0.530 ± 0.140 0.390 ± 0.129 0.351 ± 0.101 muscles relaxing essence 100 10 0.641 ± 0.186 0.310 ± 0.097**, 0.230 ± 0.042**, 0.180 ± 0.092** embodiment, 6 10 0.630 ± 0.155 0.450 ± 0.108 0.320 ± 0.123 0.330 ± 0.123 embodiment 5 10 0.570 ± 0.160** 0.330 ± 0.059**, 0.220 ± 0.111**, 0.160 ± 0.117**
Annotate: compare * * P＜0.01 with the normal saline group.
(3) this medicine has certain analgesic activity.Embodiment 5,6 can reduce because of injection due to the formaldehyde little damaged by rats or lick sufficient accumulated time, the trend that the hot plate method proof has the threshold of pain that makes mice to improve, see Table 9～10, results suggest: embodiment has analgesic effect.
Table 9. pair thermostimulation induced mice pain affect pain threshold behind group drug concentration (%) number of animals (only) medicine (%, physiological saline-12 89.6 ± 23.6 muscles relaxing essence 100 10 104.1 ± 17.3 ten thousand caul-fat 10 121.8 ± 14.5** embodiment 6 10 102.7 ± 20.4 embodiment 5 10 107.3 ± 17.5 of X ± S)
Annotate: compare * * P＜0.01 with the normal saline group.
(the group drug level number of animals (only) of X ± S) is licked or is stung sufficient accumulated time in the influence of table 10. PARA FORMALDEHYDE PRILLS(91,95) induced mice foot pain
(%) (second, normal saline-11 72.4 ± 11.7 muscles relaxing essence 100 10 58.0 ± 11.5* embodiment 6 10 66.3 ± 14.7 embodiment 5 10 60.5 ± 11.5* of X ± S)
Annotate: compare * P＜0.05 with the normal saline group.
(2) has the outgrowth effect of the local organization of promotion.Embodiment 5,6 can obviously promote the partial proliferation of fibrous tissue of pyogenic infection mice affected skin of caused by Staphylococcus aureus, 5 pairs of rat cotton balls of embodiment granuloma hypertrophy has the tendency of promotion, see Table 11, results suggest: embodiment has promoting muscle growth functions.
(X ± S) group drug concentration (%) number of animals (only) granuloma weighs (mg/100g body weight) physiological saline-10 191.2 ± 36.1 muscles relaxing essence 100 9 201.3 ± 36.0 hydrocortisones 100 9 101.0 ± 27.9** embodiment 6 50 9 201.4 ± 14.6 embodiment 5 100 9 221.2 ± 31.5 in the table 11. pair granulomatous impact of rat cotton balls
Annotate: compare * * P＜0.01 with the normal saline group.
(5) have the growth of the wound surface of promotion granulation tissue, accelerate the effect of wound repair.By dynamic observing of experimental wound granulation tissue model shown: it is totally smooth that embodiment 5,6 forms mouthful outward appearance, and color and luster is fresh and tender, and the part wound has the yellowish-brown crust to cover; See under the Electronic Speculum that fibroblast quantity is many in the granulation tissue, mitochondrion increases, rough endoplasmic reticulum is abundant, poly and free ribosome increase, tangible Golgi body occurs, collagen fiber are synthetic vigorous, and hydroxyproline content is apparently higher than the normal saline group in the granulation tissue, see Table 12～13, results suggest: embodiment 5,6 has the into function of wound granulation tissue reparation.
Table 12. embodiment, nitrofural and normal saline are to rat implementation granulation group
The real soft peculiar smell nothing of the fresh and tender sallow quality of impact (postoperative 3,4 weeks) the wound outward appearance embodiment 5 nitrofurazone physiological saline surface clean not whole color and luster of smooth clean smooth filth or a little obvious purulent secretion nothing of knitting outward appearance have crust to have or not nothing
Table 13. embodiment 5, nitrofural and normal saline are to the influence of hydroxyproline content in the granulation tissue
(mg/g, the 3rd week of the 2nd week the 1st week of the group of X ± S) the 4th all embodiment 5 10.20 ± 1.58** 19.51 ± 1.18** 23.88 ± 1.21 23.96 ± 0.82**## nitrofurals 7.03 ± 0.89## 15.84 ± 1.16## 23.50 ± 1.37## 26.37 ± 1.18 normal saline 3.45 ± 0.46 5.16 ± 0.83 11.01 ± 0.92 12.66 ± 0.84
Compare with same time nitrofural group * P＜0.01;
Compare with same time normal saline group ##P＜0.01.
(6) this medicine has a better role to experimental microcirculation disturbance, due to 5,6 pairs of epinephrines of embodiment in the lagophthalmos bulbar conjunctiva blood capillary flow velocity of blood flow slow down and the minimizing of flow all improves significantly, and can increase the opening of capillary network, see Table 14～15.Results suggest: embodiment 5,6 has the effect of blood circulation promoting and blood stasis dispelling.
The influence of 5,6 pairs of point of intersect of the capillary network countings of table 14. embodiment
Point of intersect of the capillary network (bar, the group number of animals (only) of X ± S)
Distilled water 7 5.867 behind the medicine prodrug ± 1.958 5.857 ± 1.355654-2 7 6.428 ± 2.718 10.428 ± 3.659* embodiment 67 6.000 ± 1.603 9.000 ± 1.603** embodiment 57 4.142 ± 0.833 7.143 ± 0.833**
Annotate: self compare * P＜0.05, * * P＜0.01 before and after each organizes administration.
Microcirculation change situation before the table 15-1. administration (X ± S, n=7)
Group before the administration
V (mm/s) D (μ m) S (μ m
2) Q (* 103 μ m
3/ s) distilled water 0.23 ± 0.06 9.00 ± 3.92 81.43 ± 56.21 19.00 ± 14.27654-2 0.21 ± 0.05 8.17 ± 1.48 60.71 ± 19.39 13.57 ± 7.12 embodiment 6 0.20 ± 0.03 9.57 ± 2.26 75.34 ± 36.87 14.29 ± 5.44 embodiment 5 0.19 ± 0.08 10.14 ± 3.48 97.51 ± 46.39 18.00 ± 8.28
Microcirculation change situation after the table 15-2. administration (X ± S, n=7)
Group before the administration
V (mm/s) D (μ m) S (μ m
2) Q (* 103 μ m
3/ s) distilled water 0.22 ± 0.08 8.86 ± 3.98 79.71 ± 57.31 16.86 ± 13.72654-2,0.27 ± 0.05* 10.71 ± 2.21 93.29 ± 38.71 24.30 ± 8.90* embodiment, 6 0.32 ± 0.06**, 9.43 ± 2.66 74.86 ± 39.91 22.43 ± 9.98 embodiment 5 0.31 ± 0.09** 11.86 ± 1.73 111.14 ± 42.27 34.71 ± 19.10*
Annotate: self compare * P＜0.05, * * P＜0.01 before and after each organizes administration.
Another important feature of medicine of the present invention is no obvious toxic and side effects.
(1) embodiment acute toxicity test
This experimental observation 5 pairs of animal intact skins of embodiment and damaged skin short time or repeat to smear toxicity, skin irritation and the anaphylaxis situation that administration produces.Result of the test as seen, 5 pairs of white rabbit intact skins of embodiment and damaged skin irritant reaction and matched group relatively, difference is not obvious, does not see that also abnormal change appears in animal; White guinea pig skin repeat administration was not met quick reaction.Seeing Table 16～17 shows normal and damaged skin nonirritant; Normal and the damaged skin administration to animal, no acute toxic reaction; Repeat to smear administration and do not see the generation sensitization.
5 pairs of skin irritant average response values of table 16. embodiment
Number of animals integration summation average response value
Group
(only) 1 24 48 (h) 1 24 48 (h) shone damaged skin 4440110 little intact skin 4000000 dosage damaged skins 4440110 big intact skin 4000000 dosage damaged skins 4440110 to intact skin 4000000
5 pairs of guinea pig skin influences hypersensitive of table 17. embodiment
Mus is counted average response value sensitization rate group
(only) 6 24 48 72 (h) (%) contrasts 10 00000 positive 10 1 0.95 0.80 0 100 embodiment 5 10 00000
(2) embodiment long term toxicity test
Heavy dose of administration 42 days is not seen and is caused animal appearance, behavioral activity, and food ingestion, just large and small, the hematology, blood biochemical is learned and the pathologic of important organ changes, and sees Table 18～23, shows traumatology yellow fluid safety non-toxic, can use for clinical trial.
Respectively organized the variation (14d after the group sex od 20d 42d drug withdrawal of X ± S) of rat body weight after table 18. embodiment administration 42 days and the drug withdrawal in 14 days
The intact contrast in ♀ 174.00 ± 8.43 230.50 ± 16.06 256.50 ± 14.30 281.20 ± 17.43
♂ 184.50 ± 7.97 276.50 ± 17.48 327.00 ± 30.65 359.43 ± 25.41 whole ♀ 171.50 ± 7.09 233.00 ± 19.46 253.88 ± 15.76 279.76 ± 18.36 low dosage skin ♂, 182.00 ± 7.98 269.50 ± 21.46 316.50 ± 36.43 352.31 ± 35.10 skin ♀ 170.28 ± 10.16 220.50 ± 19.01 246.00 ± 20.81 272.63 ± 24.21 high doses
♂?185.02±6.32 264.50±17.67 312.00±26.26 346.82±31.32
The broken contrast in ♀ 172.10 ± 7.24 228.46 ± 15.46 252.80 ± 16.40 276.19 ± 16.41
Decrease ♂ 180.42 ± 8.32 274.40 ± 16.21 317.21 ± 28.26 351.26 ± 19.93
♀ 170.92 ± 6.82 228.12 ± 17.12 250.21 ± 16.49 270.42 ± 20.41 low dosage skin ♂ 183.24 ± 9.21 265.50 ± 18.21 310.43 ± 19.21 348.21 ± 16.49
♀ 174.25 ± 6.42 218.42 ± 17.43 240.19 ± 18.41 266.45 ± 24.31 skin high doses
♂?179.41±8.24 260.82±18.58 300.12±24.81 342.92±20.45
The variation of table 19-1 percutaneous drug delivery rat blood index after 42 days (X ± S)
Group RBC HGB RRBC PLT
(×10
12/L) (g/L) (％) (×10
9/L)
Contrast 7.63 ± 0.58 145.30 ± 5.80 2.03 ± 0.53 838.20 ± 89.36 complete low dosages 7.25 ± 0.74 141.30 ± 8.51 2.10 ± 0.40 881.21 ± 98.24 skin high dose 7.24 ± 0.61 140.10 ± 4.38 1.87 ± 0.51 876.38 ± 94.53
Contrast 7.42 ± 0.64 140.41 ± 6.62 2.23 ± 0.72 902.24 ± 100.43 damaged low dosages 7.01 ± 0.72 138.49 ± 7.21 2.43 ± 0.49 892.41 ± 98.92 skin high dose 7.31 ± 0.45 142.24 ± 5.42 2.51 ± 0.81 884.00 ± 112.41
Table 19-2
Group WBC LYMPH MO+GR CT
(×10
9/L) (％) (％) (min)
Contrast 13.81 ± 4.21 75.40 ± 6.70 24.60 ± 5.70 3.20 ± 1.20 complete low dosages 13.48 ± 3.21 77.85 ± 5.21 22.15 ± 4.30 3.41 ± 1.41 skin high doses 13.59 ± 2.93 74.20 ± 6.80 25.80 ± 2.40 3.01 ± 1.50
Contrast 13.60 ± 5.10 78.20 ± 5.10 21.80 ± 3.10 3.43 ± 1.82 damaged low dosages 13.76 ± 5.92 76.80 ± 4.20 23.20 ± 3.21 3.61 ± 1.96 skin high doses 13.90 ± 4.12 80.00 ± 6.28 20.00 ± 4.00 3.21 ± 1.63
The variation of table 20-1 administration rat blood biochemical indexes after 42 days (X ± S)
Group ALT AST ALP TP ALB
(u/L) (u/L) (u/L) (g/L) (g/L)
Contrast 41.21 ± 10.24 159.21 ± 19.29 147.30 ± 26.27 67.20 ± 2.79 35.80 ± 4.48 complete low dosages 38.42 ± 12.41 153.10 ± 17.50 130.82 ± 48.49 66.20 ± 3.53 40.61 ± 3.01 skin high doses 39.21 ± 9.24 142.30 ± 18.94 132.00 ± 63.14 64.90 ± 4.34 39.20 ± 3.40
Contrast 42.46 ± 12.64 151.43 ± 18.43 138.62 ± 52.21 65.20 ± 3.45 34.21 ± 3.28 damaged low dosages 39.21 ± 10.41 144.26 ± 16.72 131.24 ± 38.42 62.92 ± 4.21 32.48 ± 4.01 skin high doses 39.81 ± 8.14 154.27 ± 10.12 140.08 ± 40.01 61.90 ± 4.82 31.82 ± 2.31
Table 20-2
Group GLU T-CHO T-BIL BUN Cr
(mmol/L) (mmol/L) (μmol/L) (mmol/L) (μmol/L)
Contrast 8.06 ± 0.54 4.07 ± 0.81 0.89 ± 0.61 7.89 ± 2.20 65.50 ± 8.24 complete low dosages 7.86 ± 0.96 3.97 ± 0.54 1.95 ± 0.92** 7.71 ± 1.08 68.50 ± 8.27 skin high doses 7.64 ± 0.84 3.92 ± 0.85 2.79 ± 0.69** 6.96 ± 1.76 72.80 ± 11.25
Contrast 7.81 ± 0.68 3.06 ± 0.19 0.95 ± 0.69 6.21 ± 0.73 54.34 ± 7.57 damaged low dosages 7.59 ± 0.48 3.12 ± 0.22 2.06 ± 0.98** 6.51 ± 0.64 52.52 ± 7.79 skin high dose 7.21 ± 0.62 3.01 ± 0.24 2.72 ± 1.21** 6.25 ± 0.76 56.48 ± 9.14
Annotate: compare * p＜0.05, * * p＜0.01 (down together) with matched group
The variation of table 21-1 percutaneous drug delivery each main organs coefficient of rat after 42 days (X ± S)
Organ coefficient (g/100g body weight)
Group
Conscience spleen lung kidney
Contrast 0.31 ± 0.04 3.49 ± 0.41 0.37 ± 0.15 0.59 ± 0.09 0.69 ± 0.08 complete low dosage 0.32 ± 0.04 3.75 ± 0.42 0.37 ± 0.10 0.54 ± 0.07 0.68 ± 0.08 skin high dose 0.31 ± 0.03 3.85 ± 0.43 0.37 ± 0.08 0.53 ± 0.06 0.74 ± 0.07
Contrast 0.30 ± 0.03 3.31 ± 0.45 0.36 ± 0.10 0.58 ± 0.08 0.62 ± 0.08 damaged low dosage 0.29 ± 0.04 3.26 ± 0.38 0.34 ± 0.07 0.59 ± 0.09 0.60 ± 0.07 skin high dose 0.29 ± 0.03 3.43 ± 0.40 0.35 ± 0.07 0.56 ± 0.10 0.58 ± 0.06
Table 21-2 group organ coefficient (g/100g body weight)
Intact contrast 0.14 ± 0.04 0.021 ± 0.008 0.45 ± 0.10 0.21 ± 0.04 whole skin low dosage 0.13 ± 0.03 0.023 ± 0.009 0.47 ± 0.11 0.24 ± 0.03 skin of thymus adrenal gland prostate seminal vesicle uterus ovary
Skin low dosage 0.10 ± 0.03 0.019 ± 0.008 0.50 ± 0.11 0.27 ± 0.12 skin is decreased in the broken contrast 0.11 ± 0.03 0.020 ± 0.007 0.52 ± 0.10 0.26 ± 0.09 in high dose 0.13 ± 0.04 0.021 ± 0.008 0.45 ± 0.06 0.24 ± 0.05
High dose 0.10 ± 0.03 0.021 ± 0.09 0.48 ± 0.12 0.25 ± 0.11
Table 22. embodiment percutaneous drug delivery is rat liver tissue slice check result after 42 days
Downright bad companion's cell infiltration degeneration (endochylema is loose)
Group n
-+++ +++-+++ ++ skin high dose 10 36105131 notes are decreased in+complete contrast 10 35116031 whole skin high dose 10 44205122 broken contrasts 10 25215212: (1) necrosis: "+" is dispersed in point-like or little focal necrosis for minority;
"+" is light starlike distribution all over the sky for spotty necrosis;
" ++ " is that downright bad Caulis et folium pavettae hongkongensis distributes.
(2) degeneration: 1/3 of every lobule is involved for the endochylema puffing in "+";
" ++ " be every lobule 1/3～1/2 for the endochylema puffing involves;
" +++" endochylema puffing involves more than 1/2 of every lobule.
(3) low dosage is 20 times of clinical consumption, and high dose is 60 times of clinical consumption.
Acute and sub-acute toxicity test shows that this medicine of short-term or life-time service is not seen and caused animal appearance, behavioral activity, food ingestion, just large and small, the hematology, blood biochemical is learned and the pathologic of important organ changes, and shows the embodiment safety non-toxic, can use for clinical trial.
(4) clinical adverse is observed
Show that by the inspection to blood pressure, routine blood test, Cr, BUN, GPT, bilirubin metabolism before and after 60 routine patient's medications the human physiological functions of 5 pairs of above-mentioned projects of embodiment is harmless, sees Table 23, the clinical practice that shows embodiment is safe.
Table 23. embodiment is to the influence of indexs such as patient's blood pressure, hepatic and renal function
After checking the preceding medication of group medication before the experiment
Treatment group (32) 14.54 ± 1.40 14.06 ± 1.12# systolic pressures (KPa)
Matched group (28) 14.54 ± 1.58 14.09 ± 1.16
Treatment group (32) 9.79 ± 0.93 9.03 ± 0.77## diastolic pressures (KPa)
Matched group (28) 9.34 ± 0.71 9.13 ± 0.67
Treatment group (32) 81.97 ± 8.17 82.52 ± 7.28 creatinines (μ mol/L)
Matched group (28) 84.89 ± 11.30 81.84 ± 6.32
Treatment group (32) 4.66 ± 1.19 4.60 ± 1.06# blood urea nitrogens (mmol/L)
Matched group (28) 5.24 ± 1.38 5.24 ± 1.12
Treatment group (32) 11.40 ± 3.55 10.75 ± 5.30 glutamate pyruvate transaminase (μ/L)
Matched group (28) 9.68 ± 3.50 13.22 ± 5.81
Treatment group (32) 12.77 ± 3.77 13.1 6 ± 4.15 total bilirubin (mol/L)
Matched group (28) 12.80 ± 4.95 11.70 ± 2.32
Treatment group (32) 4.54 ± 1.20 4.35 ± 1.27 bilirubin directs (mol/L)
Matched group (28) 4.32 ± 1.18 4.44 ± 0.73
Treatment group (32) 7.89 ± 2.57 8.29 ± 2.87 unconjugated bilirubins (mol/L)
Matched group (28) 7.98 ± 3.76 7.40 ± 2.15
Annotate: between two groups of * relatively;
#: compare before and after the medication;
*#：P＜0.05，##：P＜0.01
The clinical efficacy of medicine of the present invention has the following advantage that has:
(1) all can use many sick patients that plant the merging soft tissue injury, adapt to wide.
The patient who merges soft tissue injury by embodiment 5 treatments 200 routine fracture, dislocation, trauma infection contamination, soft tissue strain and contusion etc., male's 146 examples wherein, women's 54 examples, the oldest 77 years old, minimum 1.5 years old, damage location was the trunk extremity, wherein closed fracture or 122 examples of dislocating (accounting for 55.45%), soft tissue strain and contusion 19 examples (accounting for 8.6%), open fracture 44 examples (accounting for 20%), trauma infection contamination 35 examples (accounting for 15.91%).Therapeutic outcome sees the following form 24～25:
Each sick therapeutic evaluation classification fracture dislocation open fracture trauma infection contamination soft tissue strain and contusion of planting of table 24. embodiment 5 treatment adds up to produce effects 107 39 22 10 107 effective 15 2 12 8 37 invalid 03115 to add up to 122 44 35 19 220 obvious effective rates, 87.71% 88.64% 62.86% 52.63% 80.91% total effective rates 100% 93.18% 97.14% 94.74% 97.72%
The various damage individual event therapeutic evaluatioies of table 25. embodiment 5 treatments
Produce effects enabledisable total effective rate
Example number % example number % example number % example number % swelling 150 71.43 50 23.81 10 4.76 210 95.24 pain 166 79.05 40 19.05 4 1.91 210 98.10 ecchymosis 86 78.90 20 18.35 3 2.75 109 97.25 surface of a wound 57 72.15 16 20.25 6 7.60 79 92.41 red and swollen heat 680 70.83 25 26.04 3 3.13 96 96.88
Above-mentioned clinical observation shows: this medicine has definite curative effect to soft group of thin,tough silk swelling, pain, ecchymosis, local red and swollen heat pain and the wound healing that fracture, dislocation, open fracture, trauma infection contamination, soft tissue strain and contusion etc. cause.
(2) it is fast that embodiment has reducing swelling and alleviating pain, obviously reduces the advantage of traumatic infection chance, and its therapeutical effect is comprehensive.
Observe by contrast treatment with acute open soft tissue injury, external embodiment 5, acute open soft tissue injury 60 examples of 6 treatments, wherein 32 examples are organized in the embodiment treatment, medication 15～20 days, its total effective rate is 93.75%, nitrofural matched group 28 examples, its total effective rate is 85.71%, see Table 26～29, the treatment group is directly poor to reducing strong Ipsilateral week, the skin temperature difference and the partial stasis of blood of wound mouth (red) speckle, the wound surface scope, WBC all obviously is better than nitrofural group (P＜0.05), embodiment is in detumescence, pain relieving, blood stasis dispelling, recover local skin temperature, reducing wound surface suppurates, promptly occur obviously effect after 3 days in medication, and nitrofural in medication obviously effect (P＜0.05) appearred just after 7 days.The effect that shows embodiment is many-sided, it is further developing at wound early stage energy inflammation-inhibiting not only, and the middle and advanced stage in wound can promote disappearing of inflammation, quicken the absorption of local stasis of blood, improve the damaged tissue local blood circulation effectively, quicken pyrogenicity, cause the moving commentaries on classics of the pain factor, thereby reach pain relieving, the local skin temperature of reduction, promote tissue repair, the appearance that the opposing local woanded surface infects, advance wound repair.Thereby proved the merit of embodiment heat-clearing and toxic substances removing, reducing swelling and alleviating pain, blood circulation promoting and blood stasis dispelling, putrefaction-removing granulation-promoting objectively.Two groups to the curative effect of acute open soft tissue injury by contrast, and embodiment is that to have a reducing swelling and alleviating pain fast, obviously reduces the advantage of traumatic infection chance, and its therapeutical effect is comprehensive.
The comparison of table 26. liang group curative effect
The curative effect total effective rate
Group n
32 24 (75.00) 8 (18.75) 2 (6.25) 93.75 nitrofural matched groups 28 19 (67.85) 5 (17.86) 4 (14.29) 85.71 are organized in recovery from illness produce effects invalid (%) embodiment treatment
The table 27. liang open symptoms of soft tissue injuries that group is common, sign and lab testing are relatively
After the medication before the medication of observation index group
The poor treatment group 0.84 ± 0.47 in 3 days 7 days 15 days weeks footpath, (31) 1.18 ± 0.91, (32) 0.54 ± 0.71, (30) #* 0, (29) ##*, (cm) matched group 0.80 ± 0.61, (27) 1.37 ± 0.70, (25) ## 0.95 ± 0.80, (27) 0.16 ± 0.31, (25) the # stasis of blood, (red) speckle treatment group 28.44 ± 18.11, (29) 17.35 ± 18.16, (30) ## 6.59 ± 6.14, (28) ##* 0, (26) ##*, (cm
2) matched group 30.64 ± 19.40 (28) 26.10 ± 22.57 (26) 13.92 ± 12.27 (26) ## 0.42 ± 0.80 (21) ## Wound treating group 8.11 ± 6.38 (28) 2.62 ± 1.92 (29) * 1.45 ± 1.10 (27) ##* 0 (23) ## (cm
2) control group 6.68 ± 4.01 (24) 4.35 ± 3.48 (28) 2.63 ± 1.97 (26) ## 0 (19) ## skin temperature difference treatment group-0.60 ± 0.81 (32) 0.47 ± 0.89 (31) ## 0.29 ± 0.52 (30) ## 0.21 ± 0.44 (31) * ## (℃) control group-0.76 ± 1.02 (27) 0.11 ± 1.06 (27) ## 0.29 ± 1.00 (27) ##-0.07 ± 0.51 (25) #WBC treatment group, 8.47 ± 2.57 (31) 7.27 ± 1.52 (31) # 6.57 ± 1.10 (30) ##*, 7.69 ± 1.99 (30) # (* 109/L ) 8.15±1.98 ( 28 ) 7.82±2.03 ( 27 ) 7.48±1.78 ( 28 ) 7.58±1.74 ( 25 ) DC 70.62±10.52 ( 32 ) 68.97±6.97 ( 32 ) 68.94±7.21 ( 32 ) 67.97±7.82 ( 30 ) ( ％ ) 72.43±8.37 ( 28 ) 71.64±7.38 ( 28 ) 68.39±6.96 ( 28 ) # 66.16±8.02 ( 25 ) #T 36.77±0.50 ( 32 ) 36.49±0.44 ( 31 ) ## 36.43±0.44 ( 32 ) ## 36.46±0.43 ( 32 ) ## ( ℃ ) 36.98±0.34 ( 28 ) 36.59±0.40 ( 28 ) ## 36.61±0.50 ( 28 ) ## 36.55±0.49 ( 28 ) ## P 79.16±12.10 ( 32 ) 80.94±9.30 ( 32 ) 81.03±9.23 ( 32 ) 81.81±10 47 ( 32 ) ( / ) 79.48±8.23 ( 27 ) 78.18±7.91 ( 28 ) 77.70±6.09 ( 27 ) 77.50±4.87 ( 26 )
Annotate: *: treatment group matched group compares, #: compare * #:P＜0.05, ##:P＜0.01 before and after the group innerlich anwenden
Table 28. liang group is to the influence of pain
15 days pain degree treatment group treatment of control group group # treatment of control group group # treatment of control group group ## matched group * # after the medication in 7 days after the medication in 3 days after the medication before the medication
(32) severe 11100100 moderates 22 18 252100 slight 9 10 27 22 22 21 69 in (28) (32) (28) (32) (28) (32) (28) do not have 002185 26 19 anti-inflammatory rates (%), 00 6.25 3.75 25.00 17.86 81.25#* 67.86#*
Annotate: compare P＜0.05 before and after the # group innerlich anwenden;
* after the medication 15 days with medication after 3,7 days relatively, *: P＜0.05
Table 29. wound secretions situation and positive rate of bacteria
After the medication (my god) before the medication of index group
37 15 purulent secretion treatment groups, (32) 3.12, (1) 9.38, (3) * 28.12, (9) * 25.00, (8) positive rate, (%) matched group, (28) 3.57, (1) 28.57, (8) 50.00, (14) # 25.00, (7) secretions bacterize group, (32) 18.75, (6) 25.00, (8) 40.63, (13) 28.12, (9) cultivate positive rate, (%) matched group, (28) 21.43, (63) 35.71, (10) 42.86, (12) 21.43, (6)
Annotate: *: two form face purulent secretion positive rate X relatively
2Value is respectively 3.68 and 3.02,
The α value is near significant level;
#: compare #P＜0.05, positive routine number in the bracket before and after the medication.
Other embodiment of the present invention shows that having identical and akin curative effect to reach with embodiment 5, embodiment 6 does not all have obvious toxic and side effects.
The invention is not restricted to the foregoing description.
Medicine of the present invention dosage form for oral administration is also done investigation, showed akin curative effect.
Claims (13)
1. medicine for external use for the treatment of soft tissue injury is characterized in that this medicine for external use made by following medicine: Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi), Alumen, Mentholum, make water preparation, ointment, plaster or membrane dosage form; The weight ratio of each medicine is: 10～20 parts of Rhizoma Coptidis, 8～15 parts of Cortex Phellodendris, 8～15 parts of Fructus Gardeniaes, 8～15 parts of Radix Arnebiae (Radix Lithospermi)s, 2～5 parts of Alumens, 0.05～0.1 part of Mentholum.
2. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that the weight ratio of each medicine is: 12～18 parts of Rhizoma Coptidis, 10～12 parts of Cortex Phellodendris, 10～12 parts of Fructus Gardeniaes, 10～12 parts of Radix Arnebiae (Radix Lithospermi)s, 3～4 parts of Alumens, 0.07～0.08 part of Mentholum.
3. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that medicine of the present invention is the external water preparation.
4. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, it is characterized in that adding solubilizing agent in the external water preparation of the present invention.
5. according to the medicine for external use of claim 1 or 4 described treatment soft tissue injurys, the solubilizing agent that it is characterized in that external water preparation of the present invention is a glycerol.
6. the medicine for external use of treatment soft tissue injury according to claim 1 is characterized in that adding antiseptic in the external water preparation of the present invention.
7. according to the medicine for external use of claim 1 or 6 described treatment soft tissue injurys, the antiseptic that it is characterized in that external water preparation of the present invention is an ethylparaben.
8. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, the proportioning that it is characterized in that external water preparation of the present invention is: Rhizoma Coptidis 15.96kg, Cortex Phellodendri 11.4kg, Fructus Gardeniae 11.4kg, Radix Arnebiae (Radix Lithospermi) 11.4kg, Alumen 3.42kg, Mentholum 0.09kg, glycerol 45.87kg, ethylparaben 0.46kg add water and are made into 230～920 premium on currency agent.
9. according to the medicine for external use of claim 1 or 3 described treatment soft tissue injurys, it is characterized in that external water preparation of the present invention also adds Percutaneous absorption enhancer.
10. production method as the external water preparation of claim 1 treatment soft tissue injury may further comprise the steps:
A. get Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae pulverizing, add 10 times of amount 70% alcohol heating reflux 2 times, filter, filtering residue discards;
B. get Radix Arnebiae (Radix Lithospermi) in addition and be cut into 1～2cm segment, add 10 times of amount 70% alcohol at normal temperature and soak 2 times, filter, filtering residue discards;
C. Rhizoma Coptidis, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) filtrate are merged, reclaim ethanol, add Alumen to the greatest extent;
D. get Mentholum, ethylparaben adds after with a small amount of 95% dissolve with ethanol, and capacity transfer fully stirs to 90～93% of capacity, leaves standstill 24 hours in 0～4 ℃, and filter press adds glycerol again, fully stirs;
E. use the microporous filter membrane degerming, aseptic subpackaged, get product.
11. the production method of the external water preparation of treatment soft tissue injury according to claim 10, the aperture that it is characterized in that microporous filter membrane are 0.45 μ m.
12. the production method of the external water preparation of treatment soft tissue injury according to claim 10, it is characterized in that pondage to the pharmaceutical preparation capacity 90～93% after, regulating pH is between 3.7～4.0.
13. the production method of the external water preparation of treatment soft tissue injury according to claim 10 is characterized in that Rhizoma Coptidis of the present invention, Cortex Phellodendri, Fructus Gardeniae, Radix Arnebiae (Radix Lithospermi) use water extraction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96123078A CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96123078A CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1215595A CN1215595A (en) | 1999-05-05 |
| CN1056298C true CN1056298C (en) | 2000-09-13 |
Family
ID=5127578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96123078A Expired - Lifetime CN1056298C (en) | 1996-12-31 | 1996-12-31 | External use medicine for treating soft tissue injury and its producing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1056298C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693069B (en) * | 2009-08-06 | 2013-04-24 | 浙江普洛康裕天然药物有限公司 | Composition for preparing external preparation for treating soft tissue injuries and preparation method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101195010B (en) * | 2007-12-11 | 2011-09-21 | 徐欢欢 | Powder medicament for treating acute soft tissue injury |
| CN102920825B (en) * | 2012-11-08 | 2014-04-09 | 马俊龙 | Tissue regeneration promoting strengthening powder |
| CN106822321B (en) * | 2017-03-08 | 2020-06-23 | 佛山市中医院 | Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris |
| CN108653439A (en) * | 2018-06-11 | 2018-10-16 | 云南御之健医卫用品科技有限公司 | A kind of outer application disinfection oil and preparation method thereof |
| CN113577166B (en) * | 2021-08-26 | 2022-11-11 | 墨脱县人民医院 | Medicinal oil and preparation method thereof |
| CN114306710A (en) * | 2021-12-30 | 2022-04-12 | 佛山市中医院 | Medical dressing and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031174A (en) * | 1987-08-10 | 1989-02-22 | 石原产业株式会社 | Herbicidal combinations |
| CN1127129A (en) * | 1995-01-16 | 1996-07-24 | 徐永林 | External application medicine for burn and scald and preparing method |
-
1996
- 1996-12-31 CN CN96123078A patent/CN1056298C/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031174A (en) * | 1987-08-10 | 1989-02-22 | 石原产业株式会社 | Herbicidal combinations |
| CN1127129A (en) * | 1995-01-16 | 1996-07-24 | 徐永林 | External application medicine for burn and scald and preparing method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693069B (en) * | 2009-08-06 | 2013-04-24 | 浙江普洛康裕天然药物有限公司 | Composition for preparing external preparation for treating soft tissue injuries and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1215595A (en) | 1999-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1879833A (en) | An wind-expelling ointment and method for preparing same | |
| CN101028384A (en) | Medicinal composition for treating gynaecologic phlogosis, its production and quality controlling method | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1772079A (en) | Medicine for treating upper respiratory tract infection and preparation method thereof | |
| CN1212134C (en) | Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1569071A (en) | Medicine for diminishing the inflammation and reducing the pain, subsiding swelling to dissipate indurated mass, dredging meridian to removing stagnation | |
| CN1745788A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea and preparation method thereof | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN109528868A (en) | A kind of Chinese medicine composition treats aphthae in preparation, the application in the drug of carbuncle swells furunculosis | |
| CN1814221A (en) | Chinese medicine composition for treating urethra infection and preparing method | |
| CN101062085A (en) | Condyloma acuminata treating medicine | |
| CN1846770A (en) | Ointment for treating rheumatism, wound pain and swelling boil | |
| CN1240412C (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN100337658C (en) | Chinese medicine composition for treating cold anemopyretic syndrome, and its preparing method | |
| CN101077380A (en) | Antivirus medicinal composition and preparation method thereof | |
| CN1190228C (en) | Angong hemostatics | |
| CN1589892A (en) | Medicinal composition for treating acute, chronic pharyngolaryngitis and its preparation method | |
| CN1895592A (en) | Chinese-medicinal compound preparation for treating acne and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term |
Granted publication date: 20000913 |
|
| EXPY | Termination of patent right or utility model |